Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) using a proprietary cell-free platform. The STRO news page on Stock Titan aggregates company announcements, scientific updates, and regulatory disclosures so readers can follow how Sutro’s ADC pipeline and corporate strategy evolve over time.
News about Sutro frequently covers pipeline milestones, such as the initiation of a Phase 1 trial for STRO-004, a tissue factor–targeting exatecan ADC in TF-expressing solid tumors, and preclinical progress for programs like STRO-006 and the dual-payload candidate STRO-227. The company also issues updates on collaborations, including its work with Astellas on dual-payload immunostimulatory ADCs, and presentations at major scientific meetings like the World ADC Conference and the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Investors and observers will find corporate and financial communications here as well, including quarterly financial results, details of organizational restructuring aimed at extending the company’s cash runway, and information about actions related to its Nasdaq listing status, such as the 1-for-10 reverse stock split and subsequent confirmation of regained compliance with the minimum bid price requirement.
In addition, Sutro regularly announces participation in healthcare and investor conferences, virtual R&D days, and other events where management discusses the ADC platform, single- and dual-payload programs, and near- and long-term priorities. Bookmark this page to access a consolidated view of Sutro Biopharma’s latest press releases, scientific highlights, and market-facing updates related to its oncology-focused ADC pipeline.
Sutro Biopharma (NASDAQ: STRO) reported Q3 2025 results and program updates on Nov 6, 2025. Key developments include U.S. FDA IND clearance for STRO-004 with first patient dosing expected before year-end and preclinical safety to 50 mg/kg in non-human primates. The company highlighted advancing dual-payload ADC programs and collaboration progress with Astellas, including an IND-enabling tox study initiated in Q1 2025. As of Sept 30, 2025, cash, cash equivalents and marketable securities totaled $167.6M, with an expected cash runway into at least mid-2027, aided by cost reductions, restructuring, and expected near-term milestone payments.
Sutro Biopharma (NASDAQ: STRO) will host a virtual Research & Development Day on Wednesday, November 12, 2025 to present its platform innovation and next‑generation ADC pipeline.
The live webcast begins at 7:00 AM PT / 10:00 AM ET; investors can access the audio webcast at the company's investor relations events page and an archived replay will be posted after the event.
Sutro Biopharma (NASDAQ: STRO) will participate at the 16th Annual World ADC Conference in San Diego, November 3-6, 2025. Sutro plans multiple presentations and panels showcasing preclinical data on site-specific, high-DAR dual-payload ADCs, immunostimulatory ADCs, cell-free antibody manufacturing, and the discovery and development of STRO-006, a Topo1-ADC targeting integrin beta-6.
Scheduled presenters include Daniel Calarese, Gang Yin, Venkatesh Srinivasan, Krishna Bajjuri, Alice Yam, and Hans-Peter Gerber, who will join panel discussions and talks across November 3-5, 2025. Presentation materials will be posted in Sutro’s Clinical/Scientific Presentation and Publication Highlights on www.sutrobio.com after the event.
Sutro Biopharma (NASDAQ: STRO), an oncology company focused on antibody drug conjugates (ADCs), announced a significant organizational restructuring to extend its cash runway into mid-2027. The restructuring involves a workforce reduction of approximately one-third of employees.
The company aims to prioritize the advancement of its three ADC programs and research collaborations. The extended runway will support key milestones, including the planned announcement of initial clinical data from STRO-004, their next-generation Tissue Factor-targeting exatecan ADC in 2026, and the initiation of clinical studies for at least one additional ADC program.
Sutro Biopharma (NASDAQ: STRO) reported its Q2 2025 financial results and business highlights, showcasing significant progress in its ADC pipeline. The company ended Q2 with $205.1 million in cash, providing runway into early 2027. Revenue surged to $63.7 million, up from $25.7 million in Q2 2024.
Key developments include preparations for STRO-004's first-in-human trial in H2 2025, advancement of STRO-006, and progress in dual-payload ADC programs. The company secured a $7.5 million milestone payment from Astellas following an IND-enabling toxicology study. Additionally, Sutro appointed Greg Chow as CFO and established a research collaboration with the FDA to enhance ADC regulatory standards.
Sutro Biopharma (NASDAQ: STRO) has announced a significant research collaboration with the FDA to advance regulatory standards for Antibody Drug Conjugates (ADCs). The partnership will utilize Sutro's proprietary XpressCF® technology to develop reference materials and enhance analytical methods for ADC drug development.
The collaboration involves Sutro working with the FDA's Office of Pharmaceutical Quality (OPQ) to jointly lead study design and selection of target antigens, payload-linkers, and drug conjugation sites. The initiative aims to improve quality assessments and regulatory standards for both approved ADCs and those in development, with results to be published upon completion.
Sutro Biopharma (NASDAQ: STRO), a company specializing in antibody drug conjugates (ADCs) for oncology, has announced its participation in two upcoming investor conferences. The company will present at The Citizens Life Sciences Conference in New York from May 7-8, 2025, and the BofA Securities 2025 Health Care Conference in Las Vegas from May 13-15, 2025. Webcasts of both presentations will be available on Sutro's website investor relations section, with replays accessible for at least 30 days after each event.
Sutro Biopharma announced two key presentations at the 2025 AACR Annual Meeting in Chicago, showcasing their advances in antibody drug conjugates (ADCs). The company will present data on two significant developments:
- STRO-004: A novel exatecan Tissue Factor ADC showing strong anti-tumor activity and favorable safety in preclinical studies. Single-dose treatments demonstrated promising response rates in Tissue Factor-positive patient models across multiple cancers. The company plans to begin human trials later this year.
- XpressCF+® Platform: Their proprietary cell-free platform enables creation of dual-payload ADCs with higher drug-to-antibody ratios and site-selective conjugation of two linker payloads.
CEO Jane Chung highlighted that STRO-004 achieved notable disease control rates in preclinical studies. The presentations will take place on April 28, with Dr. Alice Yam presenting on STRO-004 and Dr. Gang Yin discussing dual-payload ADC development. The research demonstrates Sutro's leadership in developing next-generation cancer treatments.